#10/25/01

CH CENTER 1600/290

PURSUANT TO 37 C.F.R. § 1.10,I HEREBY CERTIFY THAT THIS PAPER (ALONG WITH ANY PAPER IDENTIFIED AS BEING A TACHED OR ENCLOSED) IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE ON THE DATE SHOWN BELOW IN AN ENVELOPE ADDRESSED as "Express Mail Post Office to Addressee" TO: COMMISSIONER OF PATENTS WASKINGTON D.C. 20231 Express Mail # ET481431525US ON: October 25, 2001

PC9919

(121*241)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BUCH ET AL

SERIAL NO: 09/512,914

ART UNIT: 1617

FILED: FEBRUARY 25, 2000

EXAMINER: S. JIANG

FOR: THERAPEUTIC COMBINATION:

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56 AND 1.97 - 1.98

Sir:

Pursuant to 37 CFR 1.97 (b) (3) and in an effort to comply with applicants' duty of disclosure under 37 CFR 1.56, the following information is hereby brought to the attention of the Examiner.

The present Information Disclosure Statement is being filed after three (3) months from the filing date of the above-identified application and after the mailing date of a First Office Action on the merits. Accordingly, Applicant has enclosed a check in the amount of \$130.00 to satisfy the requirements of 37 CFR §1.97 (c) and §1.17 (p). Should any additional fees be required by this paper, the Commissioner is hereby authorized to charge any amount which may be required by this paper to the Account of the undersigned attorneys, Deposit Account No. 03-180.00 0P

12/10/2001 01 FC:126

2775.

Respectfully submitted,

CONNOLLY BOVE LODGE & HUTZ

Rudolf E. Hutz Reg. 22,397

Connolly, Bove, Lodge & Hutz 1220 Market Street

P. O. Box 2207

Wilmington, Delaware 19899 (302) 658-9141

enclosures GMO/jab